Infliximab
| Evidence Level: L5 | Predicted Indications: 53 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Infliximab |
| DrugBank ID | DB00065 |
| Brand Names (EU) | Flixabi, Zessly |
| Evidence Level | L5 |
| Predicted Indications | 53 |
| Top Prediction Score | 93.42% |
Approved Indication (EMA)
Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | rheumatoid arthritis | 93.42% | DL |
| 2 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 90.22% | DL |
| 3 | brachydactyly-syndactyly syndrome | 89.88% | DL |
| 4 | rheumatoid vasculitis | 85.32% | DL |
| 5 | ankylosing spondylitis | 82.92% | DL |
| 6 | hypermobility of coccyx | 82.49% | DL |
| 7 | anus disease | 81.21% | DL |
| 8 | Kummell disease | 81.15% | DL |
| 9 | inflammatory spondylopathy | 80.92% | DL |
| 10 | polyarticular juvenile rheumatoid arthritis | 80.14% | DL |
| 11 | bronchitis | 77.87% | DL |
| 12 | spondyloarthropathy, susceptibility to | 77.73% | DL |
| 13 | Crohn disease of the esophagus | 77.58% | DL |
| 14 | functional neutrophil defect | 77.53% | DL |
| 15 | granulomatous disease, chronic, autosomal recessive, 5 | 77.20% | DL |
| 16 | granulomatous disease with defect in neutrophil chemotaxis | 76.88% | DL |
| 17 | inflammatory bowel disease | 76.85% | DL |
| 18 | vertebral disease | 75.14% | DL |
| 19 | WHIM syndrome | 73.11% | DL |
| 20 | osteoarthritis susceptibility | 72.62% | DL |
Showing top 20 of 53 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.